Physician profile
Maria K Grotz
NPI 1972634806
$6,081.95
in general payments reported to CMS, 2019-2025
21 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 94% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $654 · 2022: $1,219 · 2023: $1,317 · 2024: $1,552 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132 · Education: $76.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.03 |
| Education | $76.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $992.73 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $931.34 | 2023-2025 | Auvelity, Sunosi |
| Gilead Sciences, INC. | $533.56 | 2022-2025 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $456.61 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $369.94 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $366.98 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $334.66 | 2021-2025 | Spravato, Invega Sustenna |
| Biogen, INC. | $317.28 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $301.96 | 2022-2025 | Ingrezza |
| Viiv Healthcare Company | $233.07 | 2023-2024 | Apretude |
| Sunovion Pharmaceuticals INC. | $215.26 | 2021 | |
| Cequr Corporation | $150.00 | 2024 | Cequr Simplicity |
| Abbvie INC. | $136.93 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $113.84 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $111.30 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $100.04 | 2023 | |
| Corium, LLC | $98.71 | 2022 | |
| Sanofi-Aventis U.S. LLC | $96.51 | 2025 | |
| Heartflow, INC. | $89.48 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.21 | 2022 | |
| Novo Nordisk INC | $64.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Grotz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.